| Pharmaceutical Information |
| Drug Name |
Tapentadol |
| Drug ID |
BADD_D02115 |
| Description |
Opioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008. |
| Indications and Usage |
The immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy. |
| Marketing Status |
Prescription |
| ATC Code |
N02AX06 |
| DrugBank ID |
DB06204
|
| KEGG ID |
D06007
|
| MeSH ID |
D000077432
|
| PubChem ID |
9838022
|
| TTD Drug ID |
D0K4MH
|
| NDC Product Code |
Not Available |
| Synonyms |
Tapentadol | 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol | Nucynta | Tapentadol Hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C14H23NO |
| CAS Registry Number |
175591-23-8 |
| SMILES |
CCC(C1=CC(=CC=C1)O)C(C)CN(C)C |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
